BioCentury
ARTICLE | Finance

Thinking small again

Biotech 2Q12 buyside picks: Smaller caps, 1Q performers, European names

April 2, 2012 7:00 AM UTC

Buysiders shied away from small and micro-cap stocks over the last few years as poor performance and inadequate financing plagued these groups. But many investors now see them as undervalued. These include winners from last quarter, ASCO-related cancer companies and European value names.

This is the first time investors have expressed so much enthusiasm for smaller cap plays since the biotech bull market in the summer of 2009...